# Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

> **NCT02589600** · PHASE4 · COMPLETED · sponsor: **Susan L. Greenspan** · enrollment: 310 (actual)

## Conditions studied

- Osteoporotic Fractures
- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Zoledronic acid
- **DIETARY_SUPPLEMENT:** vitamin D
- **DIETARY_SUPPLEMENT:** calcium
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT02589600
- **Lead sponsor:** Susan L. Greenspan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2022-06-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589600, "Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02589600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*